Shopping Cart
- Remove All
Your shopping cart is currently empty
(9)
Apoptosis Filter
Apoptosis Cell Cycle/Checkpoint Immunology/InflammationAIM2
(4)
AhR
(27)
Antiviral
(140)
Arginase
(13)
Aryl Hydrocarbon Receptor
(30)
BCL6
(1)
CCR
(83)
CD38
(9)
CD73
(15)
COX
(400)
CXCR
(78)
Cell wall
(7)
Complement System
(53)
FKBP
(5)
FLAP
(12)
Galectin
(10)
Histamine Receptor
(253)
IFNAR
(22)
IKZF
(1)
IL Receptor
(244)
IRAK
(35)
Immunology/Inflammation related
(95)
Interleukin
(73)
LAG-3
(7)
LTR
(40)
MALT
(7)
MRP
(27)
Mucin
(3)
MyD88
(8)
NADPH-oxidase
(34)
NO Synthase
(146)
NOD
(42)
NOD-like Receptor (NLR)
(69)
NOS
(124)
Nrf2
(91)
PD-1/PD-L1
(97)
PGE Synthase
(20)
PSMA
(15)
Prostaglandin Receptor
(190)
Pyroptosis
(13)
ROS
(154)
Reactive Oxygen Species
(257)
STING
(45)
TLR
(109)
TROP2
(4)
Thrombopoietin Receptor
(4)
cGAS
(9)
gp120/CD4
(7)
PD-1/PD-L1
PD-1 (CD279) is a type I transmembrane protein composed of 288 amino acid residues, belonging to the CD28 family. It is widely expressed on a variety of immune cells, such as activated T cells, B cells, NK cells and DC cells. PD-L1 (CD274) is a ligand of PD-1, that is, a protein that can pair and bind to PD-1. It consists of 290 amino acid residues, mainly including short cytoplasmic tail region, transmembrane region, and IgV and IGC-like extracellular domains. PD-L1 is expressed in tumor cells and antigen presenting cells (APC). PD-1 and its ligand PD-L1 pathway control the induction and maintenance of immune tolerance in the tumor microenvironment. PD-1/PD-L1 activity is responsible for the activation, proliferation and cytotoxic secretion of T cells in cancer, thereby reducing the degenerate anti-tumor immune response.
T78269
RMP1-14 is an IgG-like immunoglobulin antibody against mouse PD-1 that can block PD-1 PD-L1 signaling; its isotype control antibody is Mouse IgG2a kappa, Isotype Control.
- $175
Size
QTY
Pembrolizumab
T99081374853-91-4
Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.
- $218
Size
QTY
Atezolizumab
Cited
T99021380723-44-3
Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.
- $229
Size
QTY
CitedNivolumab
T9907946414-94-4
Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.
- $182
Size
QTY
Avelumab
T99031537032-82-8
Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.
- $289
Size
QTY
Durvalumab
T111261428935-60-7
Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.
- $228
Size
QTY
AUNP-12 acetate
TP1076L
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.
- $116
Size
QTY
Anti-Mouse PD-L1 Antibody (10F.9G2)
T78270
Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.
- $70
Size
QTY
ARB-272572
T399142368182-63-0In house
ARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.
- $159
Size
QTY
BMS-202 Cited
T31461675203-84-5
BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) PD-Ll (Programmed death-ligand 1) protein protein interaction.
- $57
Size
QTY
CitedCamrelizumab
T375351798286-48-2
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1 PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.
- $163
Size
QTY
BMS-1166
T56971818314-88-3
BMS-1166 is a potent inhibitor of the PD-1 PD-L1 interaction.
- $68
Size
QTY
INCB086550
T368992230911-59-6
INCB086550 (PD-1 PD-L1-IN-8) (example 24) is a PD-1 PD-L1 inhibitor, with an IC50 <= 10 nM.
- $148
Size
QTY
PD-1/PD-L1-IN-10
T96162487550-41-2
PD-1 PD-L1-IN-10 is an orally available PD-1 PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity.
- $44
Size
QTY
BMS-8
T268591675201-90-7
BMS-8 is a novel inhibitor of the PD-1 PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.
- $33
Size
QTY
PD-1/PD-L1-IN-9
T96512628506-54-5In house
PD-1 PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1 PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
- $55
Size
QTY
BMS-1 Cited
T36551675201-83-8
BMS-1 (PD-1 PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.
- $48
Size
QTY
CitedBMS-1001 hydrochloride
T105652113650-04-5
BMS-1001 hydrochloride is an orally active inhibitor of human PD-1 PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. BMS-1001 is capable of alleviating the PD-1 PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.
- $51
Size
QTY
BMS-1001
T84702113650-03-4
BMS-1001 is a potent inhibitor of PD-1 PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).
- $56
Size
QTY
Tomivosertib Cited
T34681849590-01-7
Tomivosertib (eFT508) is a potent and highly selective MNK1 and MNK2 inhibitor with an IC50 value of 1-2 nM.
- $42
Size
QTY
CitedPROTAC PD-1/PD-L1 degrader-1
T401122447066-37-5
PROTAC PD-1 PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1 PD-L1 PROTAC that effectively inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It restores the suppressed immune response in a co-culture model of Hep3B OS-8 hPD-L1 cells and CD3 T cells and moderately decreases PD-L1 protein levels through a lysosome-dependent mechanism.
- $253
Size
QTY
N-deacetylated BMS-202
T121432310135-18-1
N-deacetylated BMS-202 is an inhibitor of PD-1 PD-L1 interactions and has potential anticancer activity for cancer research.
- $62
Size
QTY
Tislelizumab
T767031858168-59-8
Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.
- $98
Size
QTY
Evixapodlin
T364872374856-75-2
Evixapodlin (PD-1 PD-L1-IN 7) is a human PD-1 PD-L1 protein protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities.
- $113
Size
QTY
PD-L1-IN-3
T793142953044-29-4
PD-L1-IN-3 (Compound 4a) functions as an inhibitor of the PD-1 PD-L1 axis, with an IC50 value of 4.97 nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1 PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1].
- $90
Size
QTY
Nofazinlimab
T771022377845-98-0
Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody used to study unresectable hepatocellular carcinoma (uHCC) and metastatic colorectal cancer.
- $263
Size
QTY
Adebrelimab
T768992247114-85-6
Adebrelimab (SHR-1316) is a humanized monoclonal antibody targeting PD-L1 with antitumor activity for the study of solid tumors.
- $247
Size
QTY
Fraxinellone
T6S007128808-62-0
1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhibited a variety of insecticidal activities including feeding-deterrent activity, inhibition of growth, and larvicidal activity. 3. Fraxinellone has effect in the midgut metabolism of Mythimna separata (M. separata), via protease (especially the weak alkaline trypsin-like enzyme), carboxylesterase and glutathione S-transferase.
- $32
Size
QTY
Prolgolimab
T771332093956-19-3
Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.
- $163
Size
QTY
Sintilimab
T353942072873-06-2
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.
- $163
Size
QTY
LSD1-IN-27
T776352904571-94-2
LSD1-IN-27 is a potent LSD1 inhibitor with an IC50 value of 13 nM.LSD1-IN-27 inhibited the stemness and migration of gastric cancer cells.LSD1-IN-27 inhibited the expression of PD-L1 in BGC-823 and MFC cells.LSD1-IN-27 potentiated the T-cell immune response against gastric cancer.
- $158
Size
QTY
PD-1-IN-22
T123792349372-98-9In house
PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.
- $117
Size
QTY
CAY10678
T383691268709-57-4
CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPS
- $48
Size
QTY
LSD1-IN-24
T678714734-59-2
LSD1-IN-24 is a selective and potent LSD1 inhibitor with an IC50 value of 0.247 μM.LSD1-IN-24 induces PD-L1 expression and enhances the T cell killing response, and can be used in cancer-related diseases.
- $52
Size
QTY
PDL-1 cpd 10
T93592767424-13-3
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
- $50
Size
QTY
Sulfamethoxypyridazine
T084480-35-3
Sulfamethoxypyridazine (CL 13494) is a sulfanilamide antibacterial agent.
- $42
Size
QTY
LG100268
T19703153559-76-3
LG100268 is a potent, selective, and orally active retinoid X receptor (RXR) agonist that agonizes RXR-α, RXR-β, and RXR-γ at the nanomolar level, selectively exceeding the RAR by three orders of magnitude.LG100268 is capable of inducing transcriptional activation in adipocytes; affecting the RXRs and their chaperone receptor, Foxl2 Dmrt1, to induce flounder masculinization in juvenile flounder; inhibits keratin 17 expression in nigrostriatal epithelial cells; and increases PD-L1 expression in HER2 or triple-negative breast cancer.
- $60
Size
QTY
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
T40111L2691796-83-3In house
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1) programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1 PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1 PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.
- $189
Size
QTY
ARB-272572 hydrochloride
T839762377524-19-9In house
ARB-272572 hydrochloride is a small molecule PD-L1 inhibitor with an IC50 value of 400 pM for PD-1 PD-L1 HTRF.ARB-272572 hydrochloride inhibits PD-1 PD-L1 cell signaling by inducing homologous interactions with PD-L1 proteins.
- $195
Size
QTY
IMMH 010 maleate
T839702541982-47-0In house
IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.
- $195
Size
QTY
Cetrelimab
T769452050478-92-5
Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research.
- $197
Size
QTY
Dostarlimab
T768502022215-59-2
Dostarlimab (TSR-042) is a programmed cell death protein 1 (PD-1) receptor immune checkpoint inhibitor that blocks interactions with PD-L1 and PD-L2, used in the study of endometrial cancer.
- $263
Size
QTY
Zimberelimab
T767092259860-24-5
Zimberelimab (GLS-010) is a humanized monoclonal antibody targeting PD-1, with antitumor activity. It blocks the interaction between PD-L1, PD-L2, and PD-1 on the cell surface, and is used in studies of cervical cancer and non-small cell lung cancer.
- $247
Size
QTY
Retifanlimab
T771802079108-44-2
Retifanlimab (MGA-012) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Retifanlimab is used in studies of Merkel cell carcinoma.
- $247
Size
QTY
Spartalizumab
T770751935694-88-4
Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity. It blocks the interaction with PD-L1 and PD-L2, making it suitable for studying undifferentiated thyroid cancer (ATC).
- $178
Size
QTY
Envafolimab
T767152102192-68-5
Envafolimab (ASC 22) is a humanized monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), with antitumor activity. It blocks the interaction between PD-L1 and PD-1, and is used in studies of solid tumors.
- $213
Size
QTY
Ezabenlimab
T770032249882-54-8
Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.
- $197
Size
QTY
Pacmilimab
T771282145091-51-4
Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.
- $169
Size
QTY
Go to page 1
Page of 2
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.